EFB0027

AssetAlso metformin delayed release

Gut-restricted delayed-release formulation of metformin targeting the lower bowel.

Stage: Phase 1
Modality: Small molecule
Target: Mitochondrial biogenesis (PGC-1α); 1
Indication: 1,357
Trials: 1
Developer

Indications

1

Type 2 diabetes
Phase 1, Completed, NCT01677299, clinicaltrials.gov, 7 Oct 2026

In the full profile

Targets and what it contains3
Owner and partners1
Trials1,357
Evidence for its targets3
Competitors12
Aging relevance2
Signals15

Every asset’s record: target, stage, trials and the evidence behind it.